3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Sezary Syndrome
1
Sarcoma
1
Paget Disease, Extramammary
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neurofibroma
1
Mycosis Fungoides
1
Muir-Torre Syndrome
1
Microcystic adnexal carcinoma
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Liposarcoma
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Eccrine Porocarcinoma
1
Carcinoma, Signet Ring Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Basosquamous
1
Carcinoma, Basal Cell
1
Adenocarcinoma, Papillary
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
11
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
fludarabine phosphate
7
daratumumab
7
Lenalidomide
7
Bortezomib
7
carfilzomib
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
talimogene laherparepvec
×
90 days
×
Clear all
No trials found.